Colin George Wyllie Weaver

Colin George Wyllie Weaver

Auto-generated profile, based on publicly available information

Colin George Wyllie Weaver

Univ Calgary, Cumming Sch Med, Dept Community Hlth Sci, Teaching,Res & Wellness Bldg 3E18B,3280 Hosp Dr N, Calgary, AB T2N 4Z6, Canada

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 March 2015 in Nephrology Dialysis Transplantation
Verified
Journal Article
Closed access
PDF file
CWColin G. Weaver
Colin G. Weaver
PRPietro Ravani
Pietro Ravani
MOMatthew J. Oliver
Matthew J. Oliver
PAPeter C. Austin
Peter C. Austin
RQRobert R. Quinn
Robert R. Quinn
Background Poisson regression is commonly used to analyze hospitalization data when outcomes are expressed as counts (e.g. number of days in hospital). However, data often violate the assumptions on which Poisson regression is based. More appropriate extensions of this model, while available, are rarely used. Methods We compared hospitalization data between 206 patients treated with hemodialysis (HD) and 107 treated with peritoneal dialysis (PD) using Poisson regression and compared results from standard Poisson regression with those obtained using three other approaches for modeling count data: negative binomial (NB) regression, zero-inflated Poisson (ZIP) regression and zero-inflated negative binomial (ZINB) regression. We examined the appropriateness of each model and compared the results obtained with each approach. Results During a mean 1.9 years of follow-up, 183 of 313 patients (58%) were never hospitalized (indicating an excess of ‘zeros’). The data also displayed overdispersion (variance greater than mean), violating another assumption of the Poisson model. Using four criteria, we determined that the NB and ZINB models performed best. According to these two models, patients treated with HD experienced similar hospitalization rates as those receiving PD {NB rate ratio (RR): 1.04 [bootstrapped 95% confidence interval (CI): 0.49–2.20]; ZINB summary RR: 1.21 (bootstrapped 95% CI 0.60–2.46)}. Poisson and ZIP models fit the data poorly and had much larger point estimates than the NB and ZINB models [Poisson RR: 1.93 (bootstrapped 95% CI 0.88–4.23); ZIP summary RR: 1.84 (bootstrapped 95% CI 0.88–3.84)]. Conclusions We found substantially different results when modeling hospitalization data, depending on the approach used. Our results argue strongly for a sound model selection process and improved reporting around statistical methods used for modeling count data.

5 February 2020 in Journal of the American Society of Nephrology
Verified
Journal Article
Closed access
PDF file
RWRobert G. Weaver
Robert G. Weaver
MJMatthew T. James
Matthew T. James
PRPietro Ravani
Pietro Ravani
CWColin G.W. Weaver
Colin G.W. Weaver
ELEdmund J. Lamb
Edmund J. Lamb
BHBrenda R. Hemmelgarn
Brenda R. Hemmelgarn
Significance Statement: The urine albumin-to-creatinine ratio (ACR) is the preferred metric for quantifying albuminuria, and it also has been incorporated into equations to predict risk of kidney failure. However, often only the protein-to-creatinine ratio (PCR) is available. Previous studies have described the association between ACR and PCR, although none have provided a method to estimate ACR from PCR that accounts for the nonlinear association or the effect of covariates other than sex. The authors used same-sample urine ACR/PCR measurement pairs from a population-based cohort of 47,714 adults to derive equations to estimate ACR from PCR, taking into account nonlinearity and modification by several clinical characteristics. These equations may be useful in specific retrospective applications where an estimate of ACR is desired but only PCR is available. Background: Urine albumin-to-creatinine ratio (ACR) and protein-to-creatinine ratio (PCR) are used to measure urine protein. Recent guidelines endorse ACR use, and equations have been developed incorporating ACR to predict risk of kidney failure. For situations in which PCR only is available, having a method to estimate ACR from PCR as accurately as possible would be useful. Methods: We used data from a population-based cohort of 47,714 adults in Alberta, Canada, who had simultaneous assessments of urine ACR and PCR. After log-transforming ACR and PCR, we used cubic splines and quantile regression to estimate the median ACR from a PCR, allowing for modification by specified covariates. On the basis of the cubic splines, we created models using linear splines to develop equations to estimate ACR from PCR. In a subcohort with eGFR<60 ml/min per 1.73 m2, we then used the kidney failure risk equation to compare kidney failure risk using measured ACR as well as estimated ACR that had been derived from PCR. Results: We found a nonlinear association between log(ACR) and log(PCR), with the implied albumin-to-protein ratio increasing from <30% in normal to mild proteinuria to about 70% in severe proteinuria, and with wider prediction intervals at lower levels. Sex was the most important modifier of the relationship between ACR and PCR, with men generally having a higher albumin-to-protein ratio. Estimates of kidney failure risk were similar using measured ACR and ACR estimated from PCR. Conclusions: We developed equations to estimate the median ACR from a PCR, optionally including specified covariates. These equations may prove useful in certain retrospective clinical or research applications where only PCR is available.

1 September 2015 in Hypertension
Verified
Journal Article
Closed access
PDF file
CWColin G. Weaver
Colin G. Weaver
FCFiona M. Clement
Fiona M. Clement
NCNorm R.C. Campbell
Norm R.C. Campbell
MJMatthew T. James
Matthew T. James
SKScott W. Klarenbach
Scott W. Klarenbach
KMKerry A. McBrien
Kerry A. McBrien
Accurately documenting the current and future costs of hypertension is required to fully understand the potential economic impact of currently available and future interventions to prevent and treat hypertension. The objective of this work was to calculate the healthcare costs attributable to hypertension in Canada and to project these costs to 2020. Using population-based administrative data for the province of Alberta, Canada (>3 million residents) from 2002 to 2010, we identified individuals with and without diagnosed hypertension. We calculated their total healthcare costs and estimated costs attributable to hypertension using a regression model adjusting for comorbidities and sociodemographic factors. We then extrapolated hypertension-attributable costs to the rest of Canada and projected costs to the year 2020. Twenty-one percent of adults in Alberta had diagnosed hypertension in 2010, with a projected increase to 27% by 2020. The average individual with hypertension had annual healthcare costs of $5768, of which $2341 (41%) were attributed to hypertension. In Alberta, the healthcare costs attributable to hypertension were $1.4 billion in 2010. In Canada, the hypertension-attributable costs were estimated to be $13.9 billion in 2010, rising to $20.5 billion by 2020. The increase was ascribed to demographic changes (52%), increasing prevalence (16%), and increasing per-patient costs (32%). Hypertension accounts for a significant proportion of healthcare spending (10.2% of the Canadian healthcare budget) and is projected to rise even further. Interventions to prevent and treat hypertension may play a role in limiting this cost growth.

1 October 2019 in Value in Health
Verified
Journal Article
Closed access
HTHelen Tam-Tham
Helen Tam-Tham
FCFiona Clement
Fiona Clement
BHBrenda R. Hemmelgarn
Brenda R. Hemmelgarn
BMBraden J. Manns
Braden J. Manns
SKScott W. Klarenbach
Scott W. Klarenbach
KMKerry A. McBrien
Kerry A. McBrien

3 March 2022 in JMIR Research Protocols
Verified
Journal Article
Open access
CWColin George Wyllie Weaver
Colin George Wyllie Weaver
RBRobert B. Basmadjian
Robert B. Basmadjian
TWTyler Williamson
Tyler Williamson
KMKerry McBrien
Kerry McBrien
TSTolu Sajobi
Tolu Sajobi
PRPaul Everett Ronksley
Paul Everett Ronksley
Background: With the growing excitement of the potential benefits of using machine learning and artificial intelligence in medicine, the number of published clinical prediction models that use these approaches has increased. However, there is evidence (albeit limited) that suggests that the reporting of machine learning–specific aspects in these studies is poor. Further, there are no reviews assessing the reporting quality or broadly accepted reporting guidelines for these aspects. Objective: This paper presents the protocol for a systematic review that will assess the reporting quality of machine learning–specific aspects in studies that use machine learning to develop clinical prediction models. Methods: We will include studies that use a supervised machine learning algorithm to develop a prediction model for use in clinical practice (ie, for diagnosis or prognosis of a condition or identification of candidates for health care interventions). We will search MEDLINE for studies published in 2019, pseudorandomly sort the records, and screen until we obtain 100 studies that meet our inclusion criteria. We will assess reporting quality with a novel checklist developed in parallel with this review, which includes content derived from existing reporting guidelines, textbooks, and consultations with experts. The checklist will cover 4 key areas where the reporting of machine learning studies is unique: modelling steps (order and data used for each step), model performance (eg, reporting the performance of each model compared), statistical methods (eg, describing the tuning approach), and presentation of models (eg, specifying the predictors that contributed to the final model). Results: We completed data analysis in August 2021 and are writing the manuscript. We expect to submit the results to a peer-reviewed journal in early 2022. Conclusions: This review will contribute to more standardized and complete reporting in the field by identifying areas where reporting is poor and can be improved. Trial Registration: PROSPERO International Prospective Register of Systematic Reviews CRD42020206167; https://www.crd.york.ac.uk/PROSPERO/display_record.php?RecordID=206167 International Registered Report Identifier (IRRID): RR1-10.2196/30956

13 June 2021 in JMIR Preprints
Verified
Preprint
Open access
CWColin George Wyllie Weaver
Colin George Wyllie Weaver
RBRobert B. Basmadjian
Robert B. Basmadjian
TWTyler Williamson
Tyler Williamson
KMKerry McBrien
Kerry McBrien
TSTolu Sajobi
Tolu Sajobi
PRPaul Everett Ronksley
Paul Everett Ronksley
BACKGROUND With the growing excitement of the potential benefits of using machine learning and artificial intelligence in medicine, the number of published clinical prediction models that use these approaches has increased. However, there is evidence (albeit limited) that suggests that the reporting of machine learning–specific aspects in these studies is poor. Further, there are no reviews assessing the reporting quality or broadly accepted reporting guidelines for these aspects. OBJECTIVE This paper presents the protocol for a systematic review that will assess the reporting quality of machine learning–specific aspects in studies that use machine learning to develop clinical prediction models. METHODS We will include studies that use a supervised machine learning algorithm to develop a prediction model for use in clinical practice (ie, for diagnosis or prognosis of a condition or identification of candidates for health care interventions). We will search MEDLINE for studies published in 2019, pseudorandomly sort the records, and screen until we obtain 100 studies that meet our inclusion criteria. We will assess reporting quality with a novel checklist developed in parallel with this review, which includes content derived from existing reporting guidelines, textbooks, and consultations with experts. The checklist will cover 4 key areas where the reporting of machine learning studies is unique: modelling steps (order and data used for each step), model performance (eg, reporting the performance of each model compared), statistical methods (eg, describing the tuning approach), and presentation of models (eg, specifying the predictors that contributed to the final model). RESULTS We completed data analysis in August 2021 and are writing the manuscript. We expect to submit the results to a peer-reviewed journal in early 2022. CONCLUSIONS This review will contribute to more standardized and complete reporting in the field by identifying areas where reporting is poor and can be improved. CLINICALTRIAL PROSPERO International Prospective Register of Systematic Reviews CRD42020206167; https://www.crd.york.ac.uk/PROSPERO/display_record.php?RecordID=206167 INTERNATIONAL REGISTERED REPORT RR1-10.2196/30956